According to guidelines, inhaler technique should be tested in all patients, particularly those with poorly controlled asthma. We aimed to assess uncontrolled asthma patients' ability to use a pressurised metered-dose inhaler (pMDI) using the Aerosol Inhalation Monitor (AIM, © Vitalograph).
Practices invited patients for a detailed clinical review by trained asthma nurses according to practice-agreed protocols. Reviews took place from 1st April to 30th June 2008, and included checking of inhaler technique. Reasons for invitations included time since last review, asthma control, prescriptions, and adherence to medical advice. A proxy measure of control — the total number of short-acting β2-agonist (SABA) bronchodilator inhaler canisters prescribed in the previous 12 months — was used. Data on 77 pre-determined clinical parameters (including prescribing and healthcare utilisation data) were collected. Patient-completed postal symptom questionnaires (the RCP 3 questions) were obtained in some patients. All patients using pMDIs had at least two assessments using the AIM, and where appropriate inhaler technique education was provided.
2123 (24% of those invited) symptomatic asthma patients were reviewed; 1291 (61%) were using pMDIs (mean age 52 years; SD 21), of whom over 80% were in BTS/SIGN Steps 2 and 3. 1092 (85.6%) of those patients using pMDIs failed the first AIM assessment. There was a significant increase in the number of patients able to use their pMDIs correctly following instruction after the second (129 to 260 of 1197 patients, p<0.01) and third (61 to 181 of 528 patients, p< 0.01) tests. However, 78.4% and 65.7% of those tested twice and three times, respectively, failed the AIM assessment despite instruction. Logistic regression analysis failed to show any effect of age and BTS step on these outcomes.
A majority of symptomatic asthma patients in this study were unable to use pMDIs correctly. It is essential to check all patients' ability to use their prescribed inhalers regularly. Cost alone should not determine prescribing recommendations.
The EACS Service is provided by National Services for Health Improvement (NSHI) and is sponsored by Teva UK Limited.
JH is an employee of Teva UK Limited, Harlow, Essex.
MLL has accepted sponsorship from GlaxoSmithKline (GSK), AstraZeneca (AZ), Boehringer Ingelheim (BI), Cheisi, Merck Sharpe and Dohme (MSD), Merck, Altana Pharma, Novartis, Meda Pharmaceuticals, 3M Pharmaceuticals, and Schering Plough for attending conferences. He has accepted lecture fees from BI, GSK, AZ, Cheisi and Alk-Abello. He has been on advisory boards or provided consultancy for GSK, Schering Plough, MSD, Cheisi, Altana Pharma, Ranbaxy, AZ, 3M Pharmaceuticals and Novartis. He has had research grants from BI, Pfizer and GSK. He is a member of the ADMIT Group, which receives an unrestricted educational grant from MEDA pharmaceuticals. He is the former Editor-in-Chief of the PCRJ, but was not involved in the editorial review of, nor the decision to publish, this article.
About this article
Cite this article
Hardwell, A., Barber, V., Hargadon, T. et al. Technique training does not improve the ability of most patients to use pressurised metered-dose inhalers (pMDIs). Prim Care Respir J 20, 92–96 (2011). https://doi.org/10.4104/pcrj.2010.00088
Evaluation of Valved Holding Chambers Simulating Repurposing Use of Ciclesonide Metered-dose Inhaler by Patients with Pneumonia
YAKUGAKU ZASSHI (2020)
The Journal of Allergy and Clinical Immunology: In Practice (2020)
Development of an Excipient-Free Peptide Dry Powder Inhalation for the Treatment of Pulmonary Fibrosis
Molecular Pharmaceutics (2020)
Journal of the American Pharmacists Association (2019)
Pulmonary Therapy (2018)